Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr Zonder on the Importance of Personalized Medicine in Multiple Myeloma

May 21st 2025

Jeffrey Zonder, MD, discusses the importance of personalized medicine in the treatment of multiple myeloma.

FDA’s ODAC Votes in Favor of Risk/Benefit Profile of Subcutaneous Daratumumab for High-Risk Smoldering Myeloma

May 20th 2025

The FDA’s ODAC voted in favor of the risk/benefit profile of subcutaneous daratumumab in high-risk smoldering multiple myeloma.

Dr Facon on the Rationale for Evaluating Isa-VRd in Transplant-Ineligible, Newly Diagnosed Multiple Myeloma

May 20th 2025

Thierry Facon, MD, details the rationale for evaluating Isa-VRd in patients with transplant-ineligible, newly diagnosed multiple myeloma.

Dr Maroto-Martin on the Preliminary Efficacy of MZB1 TCR-Like CAR T-Cell Therapy in Myeloma

May 19th 2025

Elena Maroto-Martin, PhD, discusses early efficacy data with an MZB1-targeted TCR-like CAR T-cell therapy in multiple myeloma and Waldenström macroglobulinemia.

Dr Sobh on the Therapeutic Potential of Selectively Targeting NSD2 in Multiple Myeloma

May 19th 2025

Armin Sobh, PhD, discusses the therapeutic potential of selectively targeting NSD2 in the treatment of multiple myeloma.

Belantamab Mafodotin–Based Combos Win Japanese Approval for R/R Myeloma

May 19th 2025

Two belantamab mafodotin–based combinations have been approved in Japan for relapsed/refractory multiple myeloma.

Dr Maroto-Martin on the Development of MZB1 TCR-Like CAR T-Cell Therapy in Myeloma

May 16th 2025

Elena Maroto-Martin, PhD, discusses the rationale for developing TCR-like CAR T-cell therapy in multiple myeloma and other hematologic malignancies.

Dr Sobh on Ongoing Investigations of NSD2 in Modulating Immune Surveillance in Myeloma

May 12th 2025

Amin Sobh, PhD, discusses ongoing efforts to investigate the role of NSD2 expression in modulating immune surveillance in multiple myeloma.

Allogeneic CAR T-Cell Therapy CT0596 Yields Preliminary Efficacy and Safety in R/R Myeloma

May 12th 2025

The allogeneic CAR T-cell therapy CT0596 was safe with clinical activity in relapsed/refractory multiple myeloma.

Giants of Cancer Care® Announces the 13th Annual Class of Inductees

May 7th 2025

OncLive announces the inductees of the 13th annual Giants of Cancer Care recognition program.

FDA Grants Fast Track Designation to ISB 2001 in Relapsed/Refractory Multiple Myeloma

May 5th 2025

ISB 2001 has received fast track designation from the FDA for patients with relapsed or refractory multiple myeloma who received 3 or more prior therapies.

Five Under 5: Top Oncology Videos for the Week of 4/27

May 4th 2025

The top 5 OncLive videos of the week cover insights in colorectal cancer, prostate cancer, myeloma, renal cell carcinoma, and urothelial carcinoma.

Dr Siegel on the Evaluation of Mezigdomide for R/R Myeloma

April 30th 2025

David S. Siegel, MD, explains the rationale for assessing mezigdomide—a novel thalidomide derivative—in relapsed/refractory multiple myeloma.

Dr Sobh on the Effects of NSD2 Overexpression in Multiple Myeloma

April 29th 2025

Amin Sobh, PhD, discusses findings from a study investigating the immune surveillance–modulating capabilities of NSD2 overexpression in multiple myeloma.

Linvoseltamab Receives EC Approval for Heavily Pretreated R/R Myeloma

April 28th 2025

Linvoseltamab earned EC approval for relapsed/refractory multiple myeloma after at least 3 prior lines of therapy.

Five Under 5: Top Oncology Videos for the Week of 4/20

April 27th 2025

The top 5 OncLive videos of the week cover insights in chronic lymphocytic leukemia, ovarian cancer, multiple myeloma, and large B-cell lymphoma.

Retrospective Data Show Improved Efficacy but Higher Toxicity With Cilta-Cel vs Ide-Cel in R/R Myeloma

April 24th 2025

A multicenter review comparing ide-cel and cilta-cel in relapsed/refractory multiple myeloma showed better survival with cilta-cel but increased toxicity.

Joseph on the Research Behind the Role of Exercise and Supportive Care in Myeloma

April 23rd 2025

Janine Joseph, MS, MBA, discusses the current state of research and future directions for resistance training interventions in patients with multiple myeloma.

Dr Farid on Current and Future Investigations of MDC-CAR-BCMA001 in Myeloma and AL Amyloidosis

April 22nd 2025

Kiavasch Mohammad Nejad Farid, MD, discusses 2 planned investigations of MDC-CAR-BCMA001 in relapsed/refractory multiple myeloma and AL amyloidosis.

Salvage ASCT Shows No Long-Term PFS or OS Benefit in Relapsed Myeloma

April 22nd 2025

Salvage transplant was not associated with long-term survival benefits in relapsed/refractory multiple myeloma.